Navigation Links
Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
Date:11/1/2007

HAYWARD, Calif., Nov. 1 /PRNewswire/ -- Arete Therapeutics Inc. today announced the initiation of a phase 1 clinical trial for its lead compound, AR9281, for the treatment of hypertension. AR9281 is a "first-in-class," orally-active inhibitor of soluble epoxide hydrolase (s-EH), a novel target for the treatment of hypertension. The trial will enroll up to 32 healthy adult volunteers and will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics for single ascending doses of AR9281.

"AR9281 inhibits s-EH, an enzyme that plays a key role in the cytochrome P450 pathway of arachidonic acid metabolism, and offers a unique mechanism of action as an antihypertensive agent," said Dinesh V. Patel, Ph.D., president and chief executive officer of Arete Therapeutics Inc. "We believe this first-in-class compound has great potential to be a unique 'antihypertensive-plus' drug that not only lowers blood pressure but also offers end organ protection of the heart and kidney, and protection against vascular inflammation."

"The preclinical safety and efficacy profile of AR9281 is very encouraging and provided a solid basis for the initiation of the clinical development phase of this new compound class," commented Randall Whitcomb, M.D., chief medical officer of Arete Therapeutics Inc. "We look forward to reporting results from the initial phase 1 clinical trial in 2008."

Arete Therapeutics' phase 1 single ascending dose, placebo-controlled clinical trial in healthy volunteers will obtain initial safety and tolerance information as well as detailed blood pressure measurements. Levels of s-EH specific biomarkers will be analyzed together with typical inflammatory markers as part of the pharmacodynamic assessment. Following successful completion of the single dose study, Arete plans to initiate a multiple dose phase 1 study, a food effect study, and studies in special populations.

About AR9281

AR9281 is a novel small molecule inhibi
'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. VBI Provides Potential Targets to Diabetes Therapeutics
2. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
3. Bird Flu: Orissa Initiates Protective Measures
4. Biota Initiates Drug Testing War against Common Cold
5. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
6. Government Initiates A Program To Curb HIV
7. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
8. Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
9. Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients
10. FDA approves Phase 0 trial which tests experimental drugs on humans
11. SARS-Free Taiwan to Mark End Phase of Global Fight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics ... to go deep sea diving. The act of recreational diving exposes the ... these reasons, it is vital that all recreational and professional divers undergo regular ...
(Date:8/28/2015)... (PRWEB) , ... August 28, ... ... Services, Inc.’s (AIS) Medicare-Medicaid Dual Eligibles Database have added comprehensive information on ... alignment demonstration approved for a December 2015 launch; and Idaho’s partnership to ...
(Date:8/28/2015)... AB (PRWEB) , ... August 28, 2015 , ... External ... The Heart Fit Clinic is now selling External Counterpulsation (EECP or ECP) machines with ... Heart Fit Clinic has been in business since 2007 helping people prevent and ...
(Date:8/28/2015)... ... 2015 , ... A complimentary webinar offered by healthcare consulting and accounting firm ... proposal to mandate bundled payments through the Comprehensive Care for Joint Replacement Program ... Care for Joint Replacement,” takes place at 12 noon EDT on Wednesday, September 2, ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... Inc. ’s online medical consultations result in high percentages of change to treatment ... the Center for Healthcare Informatics at Tennessee Tech University and analyzed WorldCare’s second ...
Breaking Medicine News(10 mins):Health News:Healthpointe Now Offering Scuba Physicals 2Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:PYA Offers Complimentary CCJR Webina — Game On 2Health News:PYA Offers Complimentary CCJR Webina — Game On 3Health News:WorldCare International, Inc. Celebrates Findings of Independent ROI Study 2
... Scientists presented new research today demonstrating the impact ... studies examine how such environmental information can be transmitted ... known as epigenetics. This new knowledge could ultimately improve ... and how a parent,s exposure to drugs, alcohol, and ...
... common among cardiac arrest survivors. The survival and ... patients with preexisting cardiomyopathy, compared with those patients ... presented Nov. 14 at the at the American ... Therefore, the researchers recommended the use of therapeutic ...
... research linking alcohol to breast cancer risk, a new study ... that adolescent girls with a family history of breast disease ... cancer have a higher risk of developing benign breast ... without a family history, this already-elevated risk rises with increasing ...
... non-small cell lung cancer who have mutations in the KRAS ... according to results of a recent study conducted by Quintiles ... "Our findings indicate that when patients with lung cancer have ... to antifolate drugs," said lead researcher Sarah Bacus, Ph.D., Quintiles ...
... team of researchers co-led by the University of Pennsylvania ... capable of recording brain activity from the cortical surface ... make possible a whole new generation of brain-computer interfaces ... work was published in Nature Neuroscience. ...
... in people with dangerous heart arrhythmias, according to research ... , Wearable cardioverter defibrillators are used by people who ... including those with weakened heart function, awaiting cardiac transplant ... from receiving an implanted defibrillator. , The device ...
Cached Medicine News:Health News:Nature and nurture work together to shape the brain 2Health News:Hypothermia remains effective in cardiac arrest patients with preexisting cardiomyopathy 2Health News:Girls with family history of breast disease should avoid alcohol 2Health News:Girls with family history of breast disease should avoid alcohol 3Health News:Antifolates show promise against NSCLC subtype 2Health News:A more flexible window into the brain 2Health News:A more flexible window into the brain 3Health News:Wearable defibrillator can prevent death in people with arrhythmias 2
(Date:8/28/2015)... , August 28, 2015 The report "Eubiotics ... (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by Region ( ... Asia-Pacific , and Rest of the World) - ... global market for Eubiotics was valued at USD 4.62 Billion ... by 2020, at a CAGR of 7.4% from 2015 to ...
(Date:8/28/2015)... -- The global mHealth market ... 2020, growing at a CAGR of 47.6% from 2013 ... View Research, Inc. Monitoring services is expected to grow ... 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... of chronic diseases such as cancer, heart ailments, and ...
(Date:8/27/2015)... Aug. 27, 2015 DURECT Corporation (Nasdaq: ... present at three upcoming healthcare conferences.  ... will present at the Rodman & Renshaw Investment Conference ... The conference is being held at the St. Regis ... A live audio webcast of the presentation will be ...
Breaking Medicine Technology:Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5DURECT to Participate in Upcoming Healthcare Conferences 2
... Inc. (Nasdaq: BIOD ) will issue its third ...  Following the release of the company,s financial results, Biodel,s senior ... and provide an update on the company,s progress.August 4, 2011 ... be distributed4:15 pm EDT: , Conference call participants should dial:+1 ...
... 1, 2011 Reportlinker.com announces that a ... its catalogue: Insulin- Eastern ... This package contains 15 insulin ... countries: Bulgaria, Czech Republic, Estonia, Greece, Hungary, ...
Cached Medicine Technology:Insulin- Eastern Europe 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: